Friday, July 31, 2026

South Korea’s 20-Year Quest: Developing Electromagnetic Weapons Similar to U.S. Discombobulator

South Korea has developed electromagnetic weapon technology for offensive and defensive operations, inspired by U.S. military advancements.

Unstoppable Threat: North Korea Unleashes Precision Weapons Designed To Break US Missile Defense

North Korea's military parade marked the Workers' Party's 80th anniversary, showcasing new precision strike weapons and significant participation.

North Korea Uses Kim Il Sung’s Birthday to Cement Kim Jong Un’s Grip on Power

North Korea celebrates Kim Il Sung's 113th birthday, emphasizing loyalty to Kim Jong Un and his revolutionary achievements and plans.

Tag: cancer

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Korea’s First CAR-T Therapy Clears Initial Reimbursement Hurdle, With First Prescriptions Expected in October

South Korea's first CAR-T therapy, Rimkato, moves closer to national health insurance reimbursement, with commercialization expected by year-end.

AI Model Predicts Liver Function Decline Before Liver Cancer Treatment, Enabling More Personalized Care

South Korean researchers created an AI model to predict liver function decline in cancer patients, enhancing treatment safety and effectiveness.

ABL Bio to Launch Global Phase 3 Trial of ABL111 in December, Targeting First-Line Gastric Cancer Treatment

ABL Bio will begin global Phase 3 trials for its dual antibody gastric cancer treatment 'ABL111' this December after FDA discussions.

Bevacizumab Breakthrough: How Celltrion’s Vegzelma Secured Coverage in Major U.S. PBMs

Celltrion's Vegzelma gains preferred status with major U.S. PBMs, enhancing prescription access and boosting market share.

Hanmi Pharmaceutical completes acquisition of Aptose Biosciences

Hanmi Pharmaceutical has acquired Aptose Biosciences for $46.7 million, regaining rights to the cancer drug tuspetinib.

Celltrion’s Truxima becomes first rituximab biosimilar in U.S. to receive interchangeability designation

Celltrion's Truxima gains FDA interchangeability status, enhancing its market position and credibility in blood cancer treatment.

K-Bio shifts focus to clinical data as key trial readouts stack up in second half

Korea's biotech sector shifts focus to clinical data in H2 2023, with key results from leading companies expected to drive investor sentiment.

Unlocking Cancer Treatment: Samsung Bioepis Achieves Keytruda Biosimilar Equivalence in Global Trials

Samsung Bioepis' biosimilar SB27 shows equivalence to Keytruda in key clinical trials, enhancing access to cancer immunotherapy.

High cost keeps breakthrough VHL drug out of reach for Korean patients, oncologist says

Patients with Von Hippel-Lindau syndrome face high treatment costs, limiting access to essential drugs like Welireg, which could reduce surgeries.

Top 10 Breakthrough Research Projects from the 2026 UST Proposal Challenge

UST's Proposal Challenge showcased innovative student research aimed at solving social issues, with awards for top proposals in various fields.

Gilead Launches CAR-T Therapy Yescarta in Korea, Offering Fourfold Survival Benefit for Relapsed or Refractory Lymphoma Patients

Yescarta is widely used for second-line treatment in patients with very low survival rates, and should be adopted as a standard treatment in Korea.

ST Pharm Targets Next-Generation RNA Therapies, Positions Itself as Key CDMO Partner at BIO USA

The RNA therapeutics market is evolving, with ST Pharm aiming to lead in precision manufacturing and targeted delivery for next-gen therapies.

How K-AI Models Are Revolutionizing Cancer Treatment and Defense: A Deep Dive

South Korea's AI models excel in cancer care, shipbuilding, defense, and semiconductors, enhancing the nation's tech sovereignty.

Samsung Medical Center Named Asia-Pacific’s Top Hospital for Cancer, Respiratory and Digestive Care by Newsweek

Samsung Medical Center ranks top in Asia-Pacific for cancer, respiratory, and digestive care, showcasing its innovative treatments and high survival rates.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.